Akebia Therapeutics Beat Expectations

Akebia Therapeutics (AKBA) reported breakeven results on revenue of $62.47 million for the second quarter ended June 2025. The consensus estimate was a loss of $0.02 per share on revenue of $46.80 million. The Earnings Whisper number was a loss of $0.01 per share. The company beat expectations by 100.00% while revenue grew 43.13% on a year-over-year basis.

Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.